• Can changes in EEG improve neuropathic pain treatments - read Oct newsletter.
  • Nine posters ready to reveal at the SfN virtual conference 8-11 Nov, booth 1818.
  • Joined-up preclinical and clinical trials to advance psilocybin drug development
  • Transpharmation joins HaPpY team to help break the vicious cycle of chronic pain & mood disorders, see News for details
  • Announcing new premises in Poland with a focus on neuropsychiatric disorders...
  • New state-of-the-art premises at Discovery Park, Kent


News you can use


All the latest conference updates; those that we are attending and the studies that we are presenting

Company of the year!


Pharma Tech Outlook magazine have named Transpharmation ‘company of the year’ in their ‘top 5 UK CRO’s’ feature. We’re proud of this achievement on behalf of all the clients that we’ve worked with over the years and it’s a great start to our 10th anniversary year.

In his interview, our CEO, Mark Duxon, describes how Transpharmation differentiates itself from competitors and what his aspirations are for the company into 2020 and beyond.

You can read Mark's interview here - Read Interview




Start a Conversation

preclinical +44 (0)203 633 2807

clinical trials +353 (0)1896 42 60

clinical research +48 515 244 120

EEG contact@transpharmation.co.uk

Copyright ©2021 Transpharmation Ltd. Website created by Identity Ipswich Web Design